TrialThyroid : official journal of the American Thyroid Association2022

A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer.

Jaume Capdevila et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.